// App-Quantinova.ai

: A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone.

Researchers

Presenter

  • Roberto Pili

Principal Investigators

  • Nabil Adra

  • Theodore F. Logan

  • Heather Burney

  • Michael B. Atkins

Medical Centers

  • Department of Radiology and Imaging Sciences, Indianapolis, IN

  • Indiana University, Indianapolis, IN

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • IU Simon Comprehensive Cancer Center, Indianapolis, IN

  • University of Buffalo, Buffalo, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Entinostat

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • NCT03552380

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved